Remdesivir for COVID-19: challenges of underpowered studies
Remdesivir for COVID-19: challenges of underpowered studies
About this item
Full title
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
The authors report on 236 patients (140 [59%] men and 96 [41%] women; median age 65 years [IQR 56–71]), with inconclusive findings on the primary outcome of time to clinical improvement, defined as a two-point improvement on a 6-point ordinal scale,2 a hazard ratio of 1·23 (95% CI 0·87–1·75; favouring remdesivir), and median observation times of 21...
Alternative Titles
Full title
Remdesivir for COVID-19: challenges of underpowered studies
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7190306
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7190306
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(20)31023-0
